Research ArticleBrief Communications
Triple-Negative Breast Cancer: Early Assessment with 18F-FDG PET/CT During Neoadjuvant Chemotherapy Identifies Patients Who Are Unlikely to Achieve a Pathologic Complete Response and Are at a High Risk of Early Relapse
David Groheux, Elif Hindié, Sylvie Giacchetti, Marc Delord, Anne-Sophie Hamy, Anne de Roquancourt, Laetitia Vercellino, Nathalie Berenger, Michel Marty and Marc Espié
Journal of Nuclear Medicine February 2012, 53 (2) 249-254; DOI: https://doi.org/10.2967/jnumed.111.094045
David Groheux
Elif Hindié
Sylvie Giacchetti
Marc Delord
Anne-Sophie Hamy
Anne de Roquancourt
Laetitia Vercellino
Nathalie Berenger
Michel Marty

Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 53, Issue 2
February 1, 2012
Triple-Negative Breast Cancer: Early Assessment with 18F-FDG PET/CT During Neoadjuvant Chemotherapy Identifies Patients Who Are Unlikely to Achieve a Pathologic Complete Response and Are at a High Risk of Early Relapse
David Groheux, Elif Hindié, Sylvie Giacchetti, Marc Delord, Anne-Sophie Hamy, Anne de Roquancourt, Laetitia Vercellino, Nathalie Berenger, Michel Marty, Marc Espié
Journal of Nuclear Medicine Feb 2012, 53 (2) 249-254; DOI: 10.2967/jnumed.111.094045
Triple-Negative Breast Cancer: Early Assessment with 18F-FDG PET/CT During Neoadjuvant Chemotherapy Identifies Patients Who Are Unlikely to Achieve a Pathologic Complete Response and Are at a High Risk of Early Relapse
David Groheux, Elif Hindié, Sylvie Giacchetti, Marc Delord, Anne-Sophie Hamy, Anne de Roquancourt, Laetitia Vercellino, Nathalie Berenger, Michel Marty, Marc Espié
Journal of Nuclear Medicine Feb 2012, 53 (2) 249-254; DOI: 10.2967/jnumed.111.094045
Jump to section
Related Articles
Cited By...
- Now Is the Time to Use 18F-FDG PET/CT to Optimize Neoadjuvant Treatment in Triple-Negative Breast Cancer!
- Complete Metabolic Response on Interim 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography to Predict Long-Term Survival in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy
- 18F-FDG PET/CT for the Early Evaluation of Response to Neoadjuvant Treatment in Triple-Negative Breast Cancer: Influence of the Chemotherapy Regimen
- Quo Vadis: PET and Single-Photon Molecular Breast Imaging
- Nuclear Breast Imaging: Clinical Results and Future Directions
- Identification of Biomarkers Including 18FDG-PET/CT for Early Prediction of Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
- Baseline Tumor 18F-FDG Uptake and Modifications After 2 Cycles of Neoadjuvant Chemotherapy Are Prognostic of Outcome in ER+/HER2- Breast Cancer
- Role of Positron Emission Tomography for the Monitoring of Response to Therapy in Breast Cancer
- TBCRC 008: Early Change in 18F-FDG Uptake on PET Predicts Response to Preoperative Systemic Therapy in Human Epidermal Growth Factor Receptor 2-Negative Primary Operable Breast Cancer
- 18F-FDG PET/CT for Early Prediction of Response to Neoadjuvant Lapatinib, Trastuzumab, and Their Combination in HER2-Positive Breast Cancer: Results from Neo-ALTTO
- Comparison Between 18F-FDG PET Image-Derived Indices for Early Prediction of Response to Neoadjuvant Chemotherapy in Breast Cancer